Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01289847
Other study ID # GMX04
Secondary ID IND 12569
Status Completed
Phase Phase 4
First received January 27, 2011
Last updated December 15, 2014
Start date March 2011
Est. completion date April 2014

Study information

Verified date December 2014
Source Bio Products Laboratory
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The main objective is to determine the efficacy of Gammaplex by measuring the number of serious acute bacterial infections during treatment with Gammaplex over a 12 month period. The secondary objectives are to assess the safety and tolerability of Gammaplex and to compare the data collected from adult subjects with PID from the GMX01 study


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 16 Years
Eligibility Inclusion Criteria:

- The subject is between the ages of or is equal to 2 and 16 years of age, of either sex, belonging to any ethnic group, and above a minimum weight of 10 kg. This weight is based on the amount of blood required for testing.

- The subject has a primary immunodeficiency disease, which has as a significant component of hypogammaglobulinemia and/or antibody deficiency (e.g. common variable immunodeficiency, X-linked and autosomal forms of agammaglobulinemia, hyper-IgM syndrome, Wiskott-Aldrich Syndrome). NB Isolated deficiency of a single IgG subclass, or of specific antibodies without hypogammaglobulinemia per se, does not qualify for inclusion.

- Subjects already receiving IGIV replacement therapy require the following before their first infusion of Gammaplex:

- Documented IGIV dose(s) and treatment intervals for the last 2 consecutive routine IGIV treatments (one of which can be the screening visit result). The previous doses should also meet the following conditions before study entry: Have not changed by ± 50% of the mean dose for at least 3 months; be between 300 and 800 mg/kg/infusion; be given every 21-28 days, inclusive; be a licensed or investigational product (Phase III or IIIb).

- Documented previous IgG trough levels for the last 2 consecutive routine IGIV treatments for the last 2 consecutive routine IGIV treatments: Maintained at least 300 mg/dL above baseline serum IgG levels (defined as before initiation of any gamma globulin treatment for that subject); must be more than/equal to 600 mg/dL.

- If a subject is a female of child-bearing potential, she must have a negative result on an HCG-based pregnancy test.

- If a subject is a female who is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study.

- The subject is willing to comply with all aspects of the protocol, including blood sampling, for the duration of the study.

- The subject, if old enough (generally 6 years to 16), has signed a Child Assent Form and the subject's parent or legal guardian has signed the Informed Consent Form, both approved by the IEC/IRB.

Exclusion Criteria:

- Has not been treated with IGIV (treatment naive subject)

- The subject has a history of any severe anaphylactic reaction to blood or any blood-derived product.

- The subject is known to be intolerant to any component of Gammaplex, such as sorbitol (i.e. intolerance to fructose).

- The subject has selective IgA deficiency, history of reaction to products containing IgA, or has a history of antibodies to IgA.

- Subjects who have completed the study and subjects who have withdrawn cannot participate in the study for a second time.

- The subject is currently receiving, or has received, any investigational agent, other than an immune serum globulin (ISG) preparation that is being evaluated in a Phase III or IIIb study, within the prior 3 months.

- The subject has been exposed to blood or any blood product or derivative within the last 6 months, other than a commercially available IGIV or other forms of commercially available and licensed ISG. If an unlicensed ISG product that is in Phase III or IIIb has been given, the subject cannot be infused with Gammaplex until 20 days after the last dose was given.

- The subject is pregnant or is nursing.

- The subject, at screening, has levels greater than 2.5 times the upper limit of normal as defined at the central laboratory of any of the following: (Alanine transaminase (ALT); Aspartate transaminase (AST) Lactate dehydrogenase (LDH)).

- The subject has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for the range of the laboratory doing the analysis); the subject is on dialysis; the subject has a history of acute renal failure.

- The subject is known to abuse alcohol, opiates, psychotropic agents, or other chemicals or drugs, or has done so within the past 12 months.

- The subject has a history of DVT, or thrombotic complications of IGIV therapy.

- The subject suffers from any acute or chronic medical condition (e.g. renal disease or predisposing conditions for renal disease, or protein losing state) that, in the opinion of the investigator, may interfere with the conduct of the study.

- The subject has an acquired medical condition, such as, chronic or recurrent neutropenia (ANC < 1000 x 109/L) or AIDS known to cause secondary immune deficiency, or is post or recovering from hematopoietic stem cell transplantation.

- The subject is receiving the following medication: Systemic long-term corticosteroids (i.e. not intermittent or burst, daily, >1 mg of prednisone equivalent/kg/day).

- The subject is receiving Immunosuppressive or Immunomodulatory drugs.

- The subject has non-controlled arterial hypertension.

- The subject has anemia (hemoglobin <10 g/dL) at screening.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Biological:
Gammaplex
GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.

Locations

Country Name City State
Chile Hospital de Ninos Roberto del Río Santiago
Israel Safra Children's Hospital, Sheba Medical Center Tel-Hashomer
United States Family Allergy & Asthma Center, PC Atlanta, Georgia
United States IMMUNOe International Reseach Centers Centennial Colorado
United States Rush University Medical Center Chicago, Illinois
United States Department of Medicine, University of California Irvine California
United States Allergy, Asthma & Immunology Clinic, P.A Irving Texas
United States Children's Hospital Los Angeles Los Angeles California
United States Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States Children's Hospital of Richmond, VA Richmond Virginia

Sponsors (1)

Lead Sponsor Collaborator
Bio Products Laboratory

Countries where clinical trial is conducted

United States,  Chile,  Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events Number of subjects with serious, acute, bacterial infections as a measure of efficacy 12 months Yes
Secondary Therapeutic Efficacy Number and proportion of subjects who maintain trough IgG levels at least as high as the average of the 2 previous trough levels before the first Gammaplex infusion From week 15 onwards No
Secondary Therapeutic Efficacy Number of days off school 12 months No
Secondary Therapeutic Efficacy Number of days in hospital 12 months No
Secondary Therapeutic Efficacy Visits to physicians and/or emergency room 12 months No
Secondary Therapeutic Efficacy Number of days on therapeutic antibiotics 12 months No
See also
  Status Clinical Trial Phase
Recruiting NCT03663933 - Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation Phase 2
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Recruiting NCT05321407 - COVID-19 Vaccine Responses in PIDD Subjects
Recruiting NCT04339777 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Phase 2
Completed NCT00542997 - Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy Phase 3
Completed NCT00168025 - Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) Phase 3
Completed NCT00168012 - Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID) Phase 3
Completed NCT00004695 - Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency N/A
Completed NCT01196702 - Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
Recruiting NCT06355323 - Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France N/A
Completed NCT00322556 - Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) Phase 3
Recruiting NCT02579967 - Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies Phase 2
Recruiting NCT06145100 - Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)
Completed NCT00520494 - Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Phase 4
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Completed NCT03211689 - The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease N/A
Terminated NCT01489618 - "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency Phase 2
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Completed NCT03188419 - Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide
Not yet recruiting NCT05481554 - Composition and Function of Gut Microbiota in Porto-sinusoidal Vascular Disease Associated With Variable Common Immunodeficiency